LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of a class (the “Class”) comprising all purchasers of the securities of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ:AMRS) between November April 29, 2011 and February 8, 2012, inclusive (the “Class Period”).
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US AT 310-201-9150 OR 212-682-5340, TOLL-FREE AT 888-773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
Amyris is a renewable products company engaged in the provision of various alternatives to a range of petroleum-sourced products for the specialty chemical and transportation fuel markets worldwide. The Company builds and applies its industrial synthetic biology platform to design microbes, primarily yeast, to convert plant-sourced sugars into renewable hydrocarbons. The investigation is related to the Company’s February 9, 2012 disclosure that Amyris no longer planed to complete expansion of one of its 100-million liter production facilities. The Company further disclosed that through 2011 Amyris experienced “a significant number of operational issues” at the Company’s Biomin contract manufacturing site.
If you are a member of the Class described above and meet certain legal requirements, you may move the Court no later than July 15, 2013 to serve as lead plaintiff. To learn more, or if you purchased Amyris stock prior to the Class Period, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, or at 310-201-9150, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at 212-682-5340, Toll-Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
